Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04118738
Recruitment Status : Recruiting
First Posted : October 8, 2019
Last Update Posted : December 24, 2020
Sponsor:
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Allergy and Infectious Diseases (NIAID)
Oswaldo Cruz Foundation (Fiocruz)
Information provided by (Responsible Party):
Westat

Brief Summary:

The International Cohort Study of Children Born to Women Infected with Zika Virus (ZIKV) During Pregnancy study is a prospective, observational, international cohort study of children previously enrolled in the ZIP study or other ZIP 2.0 Protocol Team approved ZIKV-cohort study that will continue the longitudinal follow-up of children born with documented confirmed or presumptive in-utero ZIKV exposure ("ZIKV-exposed" cohort) and children born without documented confirmed or presumptive in-utero ZIKV exposure, matched by site and birth sex ("ZIKV-unexposed" cohort).

Follow-up evaluations and assessments will allow for the determination and comparison of long-term neurodevelopmental outcomes among in utero ZIKV-exposed and ZIKV-unexposed children. Each participant will be followed for about 2 years, beginning at approximately 18 months through 42 months of age.


Condition or disease
Zika Neurodevelopmental Abnormality Hearing Loss Growth Delay Eye Abnormalities

Detailed Description:

The International Prospective Observational Cohort Study of Zika in Infants and Pregnancy (ZIP) study has leveraged 10 international sites to follow mother-infant dyads prospectively in pregnancy and postpartum to determine the incidence and outcomes of Zika Virus (ZIKV) infection. The ZIP study has collected demographic, physical, environmental, laboratory, and delivery outcome data in relation to mother-infant pairs with and without ZIKV infection. Infants born to women enrolled in the ZIP study are followed for 1 year and undergo regular physical and neurological assessments to identify clinical or developmental outcomes.

The International Cohort Study of Children Born to Women Infected with Zika Virus During Pregnancy (ZIP 2.0) study will enroll children who themselves or whose biological mothers were previously enrolled in the ZIP study and other ZIP 2.0 Protocol Team-approved studies. Assessments include growth, neurodevelopmental, audiologic, ophthalmologic, and other clinical outcomes. Evaluations will occur about every 6 months over about a 2-year period beginning at approximately 18 months of age. Follow-up evaluations and assessments will allow for the determination and comparison of long-term neurodevelopmental outcomes among in utero ZIKV-exposed and ZIKV-unexposed children.

After parent(s)/legal guardian(s) permission is obtained for the child's participation in ZIP 2.0, several means to contact them will be requested. Parents will be asked whether or not messages can be left for each of the phone numbers provided and if messages can contain information regarding the nature of the study.

We expect to compare approximately 200 children with documented confirmed or presumptive in-utero ZIKV exposure and 200 controls matched by site and birth sex without documented confirmed or presumptive in-utero ZIKV exposure at age approximately 18 months, and at age 42 months.

The primary objective is to determine the long-term neurodevelopmental outcomes among children born with documented confirmed or presumptive in-utero ZIKV exposure. The secondary objectives are to compare the long-term effects (e.g., on growth, vision, hearing and neurodevelopment) of in-utero ZIKV-exposure compared to unexposed children.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy
Actual Study Start Date : June 12, 2019
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Zika Virus

Group/Cohort
ZIKV-Exposed
Children born to women with documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery or the children's laboratory documentation of confirmed or presumptive in-utero ZIKV exposure within five days of birth.
ZIKV-Unexposed
Children born to women without documented confirmed or presumptive in-utero ZIKV exposure during pregnancy through delivery and the children have no laboratory documentation of confirmed or presumptive in-utero ZIKV exposure at any time prior to ZIP 2.0 enrollment, if testing was performed prior to enrollment.



Primary Outcome Measures :
  1. Neurodevelopmental outcome at age18 months [ Time Frame: At enrollment ]
    Neurodevelopment will be measured at age 18 months (entry visit) with the Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III). The scores indicates how well the child performed compared to a group of children within the same age range.

  2. Neurodevelopmental outcome at age 24 months [ Time Frame: Six months after enrollment ]
    Neurodevelopment will be measured at age 24 months with the Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III).

  3. Neurodevelopmental outcome at age 30 months [ Time Frame: Twelve months after enrollment ]
    Neurodevelopment will be measured at age 30 months with the Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III).

  4. Neurodevelopmental outcome at age 36 months [ Time Frame: Eighteen months after enrollment. ]
    Neurodevelopment will be measured at age 36 months with the Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III).

  5. Neurodevelopmental outcome at age 42 months [ Time Frame: Twenty four months after enrollment ]
    Neurodevelopment will be measured at age 42 months with the Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III).


Secondary Outcome Measures :
  1. Anthropometric Measurements: Height [ Time Frame: At enrollment ]
    Height in centimeters will be measured at age 18 months (entry visit).

  2. Anthropometric Measurements: Height [ Time Frame: Six months after enrollment ]
    Height in centimeters will be measured at age 24 months

  3. Anthropometric Measurements: Height [ Time Frame: Twelve months after enrollment ]
    Height in centimeters will be measured at age 30 months

  4. Anthropometric Measurements: Height [ Time Frame: Eighteen months after enrollment ]
    Height in centimeters will be measured at age 36 months

  5. Anthropometric Measurements: Height [ Time Frame: Twenty-four months after enrollment ]
    Height in centimeters will be measured at age 42 months

  6. Anthropometric Measurements: Weight [ Time Frame: At enrollment ]
    Weight in kilograms will be measured at age 18 months (entry visit).

  7. Anthropometric Measurements: Weight [ Time Frame: Six months after enrollment ]
    Weight in kilograms will be measured at age 24 months (entry visit).

  8. Anthropometric Measurements: Weight [ Time Frame: Twelve months after enrollment ]
    Weight in kilograms will be measured at age 30 months (entry visit).

  9. Anthropometric Measurements: Weight [ Time Frame: Eighteen months after enrollment ]
    Weight in kilograms will be measured at age 36 months (entry visit).

  10. Anthropometric Measurements: Weight [ Time Frame: Twenty-four months after enrollment ]
    Weight in kilograms will be measured at age 42 months (entry visit).

  11. Anthropometric Measurements: Head circumference [ Time Frame: At enrollment ]
    Head circumference in centimeters will be measured at age 18 months (entry visit).

  12. Anthropometric Measurements: Head circumference [ Time Frame: Six months after enrollment ]
    Head circumference in centimeters will be measured at age 24 months.

  13. Anthropometric Measurements: Head circumference [ Time Frame: Twelve months after enrollment ]
    Head circumference in centimeters will be measured at age 30 months.

  14. Anthropometric Measurements: Head circumference [ Time Frame: Eighteen months after enrollment ]
    Head circumference in centimeters will be measured at age 36 months.

  15. Anthropometric Measurements: Head circumference [ Time Frame: Twenty-four months after enrollment ]
    Head circumference in centimeters will be measured at age 42 months.

  16. Anthropometric Measurements: Mid upper arm circumference [ Time Frame: Six months after enrollment ]
    Mid upper arm circumference in centimeters will be measured at age 24 months

  17. Anthropometric Measurements: Mid upper arm circumference [ Time Frame: At enrollment ]
    Mid upper arm circumference in centimeters will be measured at age 18 months

  18. Anthropometric Measurements: Mid upper arm circumference [ Time Frame: Twelve months after enrollment ]
    Mid upper arm circumference in centimeters will be measured at age 30 months

  19. Anthropometric Measurements: Mid upper arm circumference [ Time Frame: Eighteen months after enrollment ]
    Mid upper arm circumference in centimeters will be measured at age 36 months

  20. Anthropometric Measurements: Mid upper arm circumference [ Time Frame: Twenty-four months after enrollment ]
    Mid upper arm circumference in centimeters will be measured at age 42 months

  21. Hearing assessment: A-verage (in dB HL) of the value of Air-conduction test obtained for all frequencies measured (500Hz, 1000 Hz, 2000Hz and 4000Hz).Audiometry (VRA) [ Time Frame: At enrollment (visit 1) only if the participant missed the evaluation(s) at the 12-month ZIP study visit or is 95 or greater weeks of age at the Entry visit; then, six months after enrollment (visit 2), and 18 months after enrollment (visit 4). ]
  22. Hearing assessment: Average (in dB HL) of Bone-conduction test obtained for all frequencies measured (500Hz, 1000 Hz, 2000Hz and 4000Hz). [ Time Frame: At enrollment (visit 1) only if the participant missed the evaluation(s) at the 12-month ZIP study visit or is 95 or greater weeks of age at the Entry visit; then, six months after enrollment (visit 2), and 18 months after enrollment (visit 4). ]
  23. Hearing assessment: Proportion of children in different categories of the degree of hearing loss [ Time Frame: At enrollment (visit 1) only if the participant missed the evaluation(s) at the 12-month ZIP study visit or is 95 or greater weeks of age at the Entry visit; then, six months after enrollment (visit 2), and 18 months after enrollment (visit 4).] ]
    Proportion of children in different categories of the degree of hearing loss (Normal hearing; Mild hearing loss; Moderate hearing loss; Severe hearing loss; and Profound hearing loss). The degree of hearing loss will be determined by grouping the average of the value of Air-conduction test obtained for all frequencies measured (500Hz, 1000 Hz, 2000Hz and 4000Hz).

  24. Hearing assessment: Proportion of children in different categories of the type of hearing loss [ Time Frame: At enrollment (visit 1) only if the participant missed the evaluation(s) at the 12-month ZIP study visit or is 95 or greater weeks of age at the Entry visit; then, six months after enrollment (visit 2), and 18 months after enrollment (visit 4).] ]
    Proportion of children in different categories of the type of hearing loss (Sensorineural hearing loss; Conductive hearing loss; and Mixed hearing loss). The type of hearing loss will be established by comparing the mean of air-conduction levels.

  25. Hearing assessment: Proportion of children with abnormal results in the Otoacustic Emissions test. [ Time Frame: Time Frame: At enrollment only if the participant missed the evaluation(s) at the 12-month ZIP study visit or is 95 or greater weeks of age at the Entry visit; then, six months after enrollment, and 18 months after enrollment. ]
  26. Comprehensive ophthalmologic evaluation. [ Time Frame: At enrollment (visit 1) only if the participant missed the evaluation(s) at the 12-month ZIP study visit or is 95 or greater weeks of age at the Entry visit; then, six months after enrollment (visit 2), and 18 months after enrollment (visit 4). ]
    General examination of eye structure and assessment of visual function. Composite measure of Visual function based on visual behaviors (with minimum and maximum possible values of -6 and +6, respectively).

  27. Comprehensive ophthalmologic evaluation [ Time Frame: At enrollment (visit 1) only if the participant missed the evaluation(s) at the 12-month ZIP study visit or is 95 or greater weeks of age at the Entry visit; then, six months after enrollment (visit 2), and 18 months after enrollment (visit 4) ]
    Composite measure of Retina evaluation (with minimum and maximum possible values of -14 and +14, respectively).

  28. Comprehensive ophthalmologic evaluation [ Time Frame: At enrollment (visit 1) only if the participant missed the evaluation(s) at the 12-month ZIP study visit or is 95 or greater weeks of age at the Entry visit; then, six months after enrollment (visit 2), and 18 months after enrollment (visit 4).] ]
    Composite measure of Optic Nerve evaluation (with minimum and maximum possible values of -12 and +12, respectively


Biospecimen Retention:   Samples With DNA
blood and urine samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Months to 42 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Approximately 200 children with confirmed or presumptive in-utero exposure to Zika virus and approximately 200 children matched by site and birth sex without confirmed or presumptive in-utero exposed to Zika virus.
Criteria

Inclusion Criteria:

ZIKV- Exposed Inclusion Criteria:

  • Parent(s)/legal guardian(s) provided written permission for his or her child to participate.
  • Participant and/or participant's biological mother previously enrolled in the ZIP study or other ZIKV cohort study approved by the sponsors.
  • Participant's biological mother has laboratory documentation of positive ZIKV RNA test results during pregnancy through delivery delivery or the participant has laboratory documentation of ZIKV RNA or serology positive/presumptive positive/equivocal ZIKV test within 5 days of birth according to the ZIKV-exposed definitions included in the ZIP 2.0 inclusion criteria.
  • Minimum 74 weeks of age (approximately 17months) of age at enrollment

ZIKV-Unexposed Inclusion Criteria:

  • Parent(s)/legal guardian(s) provided written permission for his or her child to participate.
  • Previously enrolled in the ZIP study and identified as matching the same birth sex and followed at the same study site as an enrolled ZIKV-exposed participant.
  • Laboratory documentation that the participant's biological mother has negative ZIKV RNA test results and no positive ZIKV RNA test results at any time during her pregnancy through delivery.
  • Participant did not test ZIKV RNA and/or serology positive presumptive positive or equivocal at any time prior to ZIP 2.0 enrollment, if testing was performed prior to enrollment.
  • Minimum 74 weeks of age (approximately 17months) of age at enrollment

Exclusion Criteria: Both Exposed and Unexposed Cohorts

• Enrolled in other clinical research (including other ZIKV research) requiring blood collection, which in combination with ZIP 2.0 evaluations, would exceed the lesser of 50 mL or 3 mL per kg in an 8-week period and/or blood collection would be required more frequently than two times per week.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04118738


Contacts
Layout table for location contacts
Contact: Dina Monte, RN, BSN 914-591-6170 dinamonte@westat.com
Contact: Isabel Trejos, PharmD, MSc 240-401-2175 isabeltrejos@westat.com

Locations
Layout table for location information
Brazil
Departamento de Medicina Tropical da Universidade Federal de Pernambuco- UFPE Recruiting
Recife, Pernambuco, Brazil, 50670-901
Contact: Gabriela Fulco    (55) 21 3885-1616    raaximenes@uol.com.br   
Contact: Ernesto Marques       marques@PITT.edu   
Principal Investigator: Ricardo A. de Alencar Ximenes, MD         
Instituto Fernandes Figueira - FIOCRUZ Recruiting
Rio De Janeiro, Brazil, 22250-020
Contact: Tatiana C. Senna    (81) 2123-7846    tatianacsenna@gmail.com   
Contact: Guto Galvao       luiz.galvao@fiocruz.br   
Principal Investigator: Maria Elisabeth L. Moreira         
Colombia
Centro Médico Imbanaco (CMI) Not yet recruiting
Cali, Colombia, 760031
Contact: Juan Arias       juan.arias@stjude.org   
Contact: Dayana Pino       pinodayana@gmail.com   
Principal Investigator: Juan Arias         
Peru
Asociación Civil Selva Amazónica Recruiting
Iquitos, Loreto, Peru, 16001
Contact: Nohelia Gamboa    51 065 236277    ogamboa@acsaperu.org   
Contact: Cesar Ugarte    51-1-4823903    cesar.ugarte@upch.pe   
Principal Investigator: Theresa Ochoa         
Puerto Rico
Puerto Rico Medical Center- Maternal Infant Studies Center (CEMI) Recruiting
San Juan, Puerto Rico, 00936
Contact: Dianca Sierra    787-753-5913    dianca.sierra@upr.edu   
Contact: Carmen Zorrilla       carmen.zorrilla@upr.edu   
Principal Investigator: Carmen Zorrilla         
Sponsors and Collaborators
Westat
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Allergy and Infectious Diseases (NIAID)
Oswaldo Cruz Foundation (Fiocruz)
Investigators
Layout table for investigator information
Study Chair: Deolinda MF Scalabrin, MD, PhD Research Center- FIOCRUZ Brazil
Study Chair: Marisa M. Mussi-Pinhata, MD, MD Ribeirão Preto Medical School- University of Sao Paulo
Study Chair: Maria Elisabeth L Moreira, MD Instituto Fernandes Figueira - FIOCRUZ
Layout table for additonal information
Responsible Party: Westat
ClinicalTrials.gov Identifier: NCT04118738    
Other Study ID Numbers: ZIP 2.0
First Posted: October 8, 2019    Key Record Dates
Last Update Posted: December 24, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Westat:
ZIKA
Additional relevant MeSH terms:
Layout table for MeSH terms
Hearing Loss
Eye Abnormalities
Congenital Abnormalities
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Eye Diseases